INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $21,000 | -69.6% | 367 | -78.4% | 0.00% | -66.7% |
| Q2 2021 | $69,000 | +68.3% | 1,700 | +7.5% | 0.00% | 0.0% |
| Q3 2020 | $41,000 | +485.7% | 1,582 | +274.0% | 0.00% | +200.0% |
| Q1 2020 | $7,000 | -73.1% | 423 | -42.5% | 0.00% | -50.0% |
| Q4 2019 | $26,000 | +188.9% | 736 | -35.7% | 0.00% | +100.0% |
| Q3 2019 | $9,000 | -62.5% | 1,145 | -39.0% | 0.00% | -50.0% |
| Q2 2019 | $24,000 | +500.0% | 1,878 | +501.9% | 0.00% | – |
| Q1 2019 | $4,000 | -50.0% | 312 | -57.8% | 0.00% | -100.0% |
| Q4 2018 | $8,000 | +300.0% | 739 | +396.0% | 0.00% | – |
| Q2 2017 | $2,000 | -83.3% | 149 | -80.1% | 0.00% | -100.0% |
| Q1 2017 | $12,000 | -60.0% | 748 | -62.9% | 0.00% | -66.7% |
| Q4 2016 | $30,000 | -69.7% | 2,016 | -43.6% | 0.00% | -66.7% |
| Q1 2016 | $99,000 | – | 3,574 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |